TP53 and acute myeloid leukemia: The anti-CD47 antibody magrolimab in combination with azacitidine showed a 57% CR/CRh rate in patients with treatment-naïve AML (65% had TP53 mutation) who were ineligible for intensive therapy in a phase 1b study.